NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Open purchase orders reached $5.4 million for shipments through fiscal first-quarter 2027, with delivery schedules still a dependency.

Rhea-AI Summary

NeuroOne Medical Technologies (NMTC) expects preliminary fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% year over year. The quarter ended September 30, 2026, compares with approximately $2.7 million in fiscal fourth-quarter 2025. Expected full-year product revenue is approximately $10.5 million, up 15.6% and at the top of the prior $9.2 million–$10.5 million guidance range.

In September, NeuroOne secured a $4.5 million purchase order, its largest ever, and shipped approximately $1.0 million of it. Remaining shipments are expected to begin in fiscal first-quarter 2027 and continue into the second quarter, subject to manufacturing and delivery schedules. Open purchase orders for shipments through fiscal first-quarter 2027 reached $5.4 million as of September 30. Fiscal 2026 product orders increased 24.2%. The revenue figures are unaudited and subject to year-end accounting and audit adjustments.

5 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointSeptember's $4.5 million purchase order was NeuroOne's largest; approximately $1.0 million shipped that month. 44% of market cap
• Major pointOpen purchase orders increased to $5.4 million as of September 30, for shipments through fiscal first-quarter 2027. 53% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Preliminary fiscal Q4 2026 product revenue expected at approximately $3.8 million, up 38.4% year over year.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Preliminary fiscal 2026 product revenue expected at approximately $10.5 million, up 15.6%, topping prior $9.2 million–$10.5 million guidance.
• Moderate pointFiscal 2026 product orders increased 24.2% compared with fiscal 2025.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Remaining September-order shipments expected in fiscal Q1–Q2 2027 depend on manufacturing and delivery schedules.
• Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary, unaudited revenue figures remain subject to adjustment after year-end accounting and audit procedures.

News Explained

The revenue figures are still preliminary and may change after year-end accounting and audit procedures; NeuroOne expects complete fiscal 2026 results in December 2026 alongside its Annual Report on Form 10-K.

Argus 15 min delay 17 alerts

+3.57% vs previous close $1.16 last price 88.8x rel. volume Open Argus

Details

Market move: NMTC +3.57% vs previous close. FY2026 preliminary revenue report

+10.7% Peak in 3 min

$1.04 – $1.27 Day Range

$10.56M Market Cap

On Oct 5, the day this news came out, the latest delayed price for NMTC is 3.57% above the previous close. Argus tracked a peak move of +10.7% during the session. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $1.16. Relative volume is exceptionally heavy at 88.8x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Q4 product revenue: Approximately $3.8 million Full-year product revenue: Approximately $10.5 million Record purchase order: $4.5 million +3 more

Q4 product revenue

Approximately $3.8 million

Preliminary fiscal Q4 2026; 38.4% year-over-year growth versus approximately $2.7 million in Q4 fiscal 2025

Full-year product revenue

Approximately $10.5 million

Preliminary fiscal 2026; 15.6% year-over-year growth and at the top of the $9.2 million to $10.5 million guidance range

Record purchase order

$4.5 million

Largest product purchase order in the Company's history, secured in September 2026

Order amount shipped

Approximately $1.0 million

Shipped in September 2026 from the $4.5 million purchase order

Remaining order shipments

$3.6 million

Expected to begin in fiscal Q1 2027 and continue into fiscal Q2 2027, subject to manufacturing and delivery schedules

Open purchase orders

$5.4 million

For shipments through fiscal Q1 2027, as of September 30, 2026

Key Terms

form 10-k, generally accepted accounting principles, fda-cleared

3 terms

form 10-k regulatory

"in conjunction with the filing of the Company's Annual Report on Form 10-K"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

generally accepted accounting principles financial

"prepared in accordance with United States generally accepted accounting principles"

Generally accepted accounting principles (GAAP) are a standardized set of rules and practices companies use to record and report their financial results, like a common recipe so dishes from different cooks can be fairly compared. Investors rely on GAAP because it makes company earnings, assets and liabilities consistent and transparent across businesses, helping them compare performance, spot risks, and make informed decisions about buying or selling stock.

fda-cleared regulatory

"four FDA-cleared product families"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025. For the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.

In September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history. Approximately $1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules. Following receipt of this order, total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million as of September 30, 2026. This record purchase order provides greater visibility into anticipated product shipments, cash flow and revenue opportunities as the Company enters fiscal 2027.

“Momentum continues to build across our business,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery platform.”

Complete financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with the filing of the Company's Annual Report on Form 10-K with the Securities and Exchange Commission.

The selected unaudited financial results included in this press release are preliminary and subject to the completion of year-end accounting and audit procedures and are therefore subject to adjustment. This preliminary financial information is the responsibility of management and has been prepared in good faith on a basis consistent with prior periods. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences regarding the Company's financial information that is not provided. This preliminary financial information should not be viewed as a substitute for complete financial statements prepared in accordance with United States generally accepted accounting principles.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue", "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the fourth quarter and full fiscal year 2026 revenue amounts, international market expansion, and the launch of our drug delivery program. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group - MZ North America
949-491-8235

NMTC@mzgroup.us

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary fiscal 2026 revenue does NeuroOne expect?

NeuroOne expects fiscal 2026 product revenue of approximately $10.5 million, representing 15.6% year-over-year growth. That is the top of its previously announced $9.2 million to $10.5 million guidance range. The figures are preliminary, unaudited and subject to adjustment.

How large is NeuroOne's record purchase order, and when will it ship?

NeuroOne secured a $4.5 million product purchase order in September 2026, its largest ever. Approximately $1.0 million shipped in September. Remaining shipments are expected to begin during fiscal first-quarter 2027 and continue into fiscal second-quarter 2027, subject to manufacturing and delivery schedules.

When will NeuroOne announce complete fiscal 2026 financial results?

NeuroOne expects to announce complete fourth-quarter and full-year fiscal 2026 financial results in December 2026, alongside the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.